Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-9-17
pubmed:abstractText
(i) To model the effects of the monoclonal antibody ATM-027 on the number of target cells and on the receptor density on the cell surface as measured by Fluorescence Activated Cell Sorter analysis, (ii) to investigate the effects of categorizing a continuous scale, and (iii) to simulate a phase II trial from phase I data in order to evaluate the predictive performance of the model by comparison with the actual trial results.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-10511060, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-11259992, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-11697751, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-11882056, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-11921052, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-11994053, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-1375472, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-1637781, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-1706680, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-761446, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-7924127, http://linkedlifedata.com/resource/pubmed/commentcorrection/15373930-8938565
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0306-5251
pubmed:author
pubmed:copyrightInfo
Copyright 2004 Blackwell Publishing Ltd
pubmed:issnType
Print
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
378-89
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS.
pubmed:affiliation
AstraZeneca R&D Södertälje, Sweden. per-henrik.zingmark@astrazeneca.com
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II, Clinical Trial, Phase I